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ABSTRACT
Clinicians had suspected for years that drug eruptions were probably mediated by immune mechanisms be-
cause their timing suggested sensitization and specific immunologic memory rather than direct toxicity. An im-
mune response to medications was also demonstrated by positive skin tests and by several types of in vitro
tests that evidenced immediate or delayed hypersensitivity.
In the last decade several teams of researchers obtained in vitro drug-specific human T-cell clones, in a variety
of clinical types of drug eruptions. These clones were produced from blood or skin mononuclear cells of pa-
tients with a history of drug reaction by stimulation in vitro with drug. They were either of CD4 or CD8 pheno-
types. Drug specific clones were stimulated by the parent drug much more often than by reactive metabolites.
That challenged the classical “hapten hypothesis” that the immune response was initiated by reactive metabo-
lites combined to self proteins. The medication usually stimulated specific T-cells after non-covalent binding to
major histocompatibility (MHC )molecules on antigen presenting cells . In toxic epidermal necrolysis , T-
lymphocytes present at the site of lesions, exhibited a drug specific cytotoxicity against autologous target cells,
or allogeneic cells that shared the same HLA than autologous cells. This MHC class I restriction and mediation
of death by perforingranzyme release, is the classical behavior of cytotoxic T lymphocytes, like those operat-
ing in the reject of a transplanted organ. MHC restriction could explain the key role of HLA genes as predispos-
ing factors to severe drug reactions. A strong association between HLA and hypersensitivity to abacavir, SJS or
TEN to carbamazepine or allopurinol has been recently demonstrated. Resemblance to graft rejection points to
the possible therapeution value of immuno suppressive agents．
Most drug eruptions appear to result from T-cell mediated delayed hypersensitivity. The secondary activation of
different cascades of cytokines, may contribute to the heterogeneity of clinical presentations．
KEY WORDS
autologous, cytotoxicity, drug hypersensitivity, epidermal, HLA, immunologic, T-lymphocytes, toxic
INTRODUCTION
Drug reactions are a public health problem because
of their frequent occurrence, occasional severity and
impact on the use of medications.1 The skin is among
the organs most often affected by adverse drug reac-
tions. The list of conditions that can be triggered by
medications includes nearly all dermatological dis-
eases. Many of these adverse reactions result from
mechanisms that do not involve an immunological
process. For example the accumulation of drug de-
rived compounds in the skin can result in hyperpig-
mentation ( amiodarone , antimalarials , minocycline ,
quinolones) . A pharmacologic interaction with the
proliferation and differentiation of epidermis, hair fol-
licles or sebaceous glands can induce alopecia(cyto-
statics), folliculitis(anti-EGF)or severe dryness(isot-
retinoin) . Such side-effects are usually delayed by
weeks or months, and sometimes relatively common
among long term users of these drugs, i.e. very spe-
cific and limited populations. In such groups these re-
actions are expected, and the prescribing physician
can easily evaluate the benefitrisk ratio and often
also provide advises for preventing or alleviating the
adverse effects.
The situation is different for drug eruptions that de-
velop soon after the introduction of a medication. Sev-
eral large cohorts have shown that such reactions oc-
cur in 2 to 3% of unselected hospitalized patients.2,3
More and more data suggest that these eruptions
have an immunological basis. Fortunately about 90%
of theses reactions are benign and transient “maculo-
papular rashes”，3 but severe cutaneous adverse reac-
tions(SCAR) to drugs nevertheless affect about 1 per
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1000 hospitalized persons.4
In this situation the occurrence of the reaction is
non predictable, even if some factors are known to in-
crease the risk. The severity is also rather difficult to
assess at the early onset of the rash, often leading to
the discontinuation of a useful treatment. Further use
of medications is compromised because patients con-
sider themselves as potentially“allergic” to every
medication. It is therefore of tremendous importance
to better understand the basic mechanisms of benign
and severe drug reactions in order to improve the
management of a variety of situations, from the early
pre-clinical phase of the development of a new drug,
to the design of tests that could help in clinical prac-
tice for assessing drug causality and providing clear
recommendations for future use of medications in in-
dividual patients．
Taking for granted that most drug reactions are al-
lergic , many questions still need clarification . Is
chemical reactivity a key determinant for a medica-
tion being antigenic? Which differences in the im-
mune response lead to rare and life-threatening reac-
tions rather than to benign and common eruptions?
Can we suspect that some risk factors for drug reac-
tions play a role through interaction with the immune
response? How should we use our improved knowl-
edge of mechanisms for prevention and treatment of
drug allergy？
MOST DRUG ERUPTIONS ARE PROBABLY
“ALLERGIC”
Up to recently, the main argument was the timing of
drug eruptions. Most begin one to three weeks after
the introduction of the medication, while recurrences
after re-challenge begin within 2 days. This timing
suggests sensitization and a specific immunologic
memory rather than direct toxicity, which should oc-
cur when a dose related threshold is reached. It is not
yet understood why mild eruptions usually occur 9 ±
5 days after initiation of the medication, when most
severe reactions often begin later : 14 ± 7 days for
Stevens-Johnson syndrome(SJS)or Toxic Epidermal
Necrolysis(TEN), 28 ± 14 days for“drug hypersensi-
tivity syndrome” (DHS)also called“drug reaction
with eosinophilia and systemic symptoms(DRESS).
Some eruptions occur much sooner : minutes to
hours for urticaria and anaphylaxis, 1 to 3 days for
“acute generalized exanthematous pustulosis(AGEP)
and fixed drug eruption(FDE). It is usually proposed
that AGEP and FDE are recall reactions after prior
overt or latent sensitization．
There is a large amount of data in the medical lit-
erature on in vivo and in vitro immunologic tests to
medications. Penicillin allergy has been extensively
studied . The antigenic determinants of immediate
IgE-related reactions were determined and the posi-
tive or negative predictive value of prick-tests has
been evaluated as rather good. For the more frequent
delayed eruptions, to penicillins or to other drugs, the
sensitivity and predictive value of skin tests is
poorer.5 Even if not as helpful as expected in daily
clinical practice, positive skin tests to drugs demon-
strate a specific sensitization to medications and biop-
sies of positive tests have been used for isolation of
drug-specific T-cells.6 The situation is similar for the
many in vitro tests that had been developed . The
overall relationship between positive in vitro tests and
eruptions strongly supports the existence of an im-
mune response to drugs, but the predictive values are
not high enough to be useful for clinical decisions in
individual patients.
Many studies of drug eruptions using immunola-
belling of skin biopsies demonstrated the presence in
the lesions of activated T-cells , with usually a pre-
dominance of CD4 + lymphocytes in the dermis and a
predominance of CD8 + cells in the epidermis.7,8
In guinea-pigs immunized by injection of cepha-
losporins in complete Freund adjuvant, peritoneal in-
jection of the sensitizing drug resulted in a wide-
spread eruption . The reactivity was transferred to
naïve recipients occasionally by the serum and
nearly always by lymphocytes from the spleen or
lymph nodes from sensitized animals. T lymphocytes
were probably responsible for the reaction since it
was not abrogated by the depletion of B lymphocytes
from the transferred cells.9
MEDICATION SPECIFIC T-CELL CLONES
In the last decade the key role of drug specific T-cells
in drug allergy was definitely demonstrated by the es-
tablishment of human T-cell clones, derived from the
blood lymphocytes or from skin lesions of patients
with a variety of reactions.10-15 Since these clones had
been obtained after several stimulations in vitro with
the drug, their relevance to explain the original mani-
festations of allergy can be questioned. Anyhow T-cell
clones provided the demonstration that drugs can be
recognized by human T-cells and suggested original
pathways of activation. Clones have been obtained
with most medications that induce allergic reactions
in man including penicillin G , amoxicillin , cepha-
losporins , sulfamethoxazole , phenobarbital , car-
bamazepine, lamotrigine . They were often of both
CD4 and CD8 phenotype, whatever the original type
of eruption had been, with a majority of CD4+ clones.
Some clones produced a Th0 profile of cytokines(si-
multaneous release of IL4 and IFN-gamma). A Th2
orientation was frequent in CD4+ clones while CD8+
clone were usually Th1 and often cytotoxic . Drug
presentation to T-cell was MHC restricted, usually as
expected by HLA class II for CD4+ cells and by HLA
class I for CD8. But there was also less classical situ-
ations like HLA class II restricted cytotoxic CD4
clones.16,17 With many drugs a very original observa-
tion was that the drug could be presented to the TCR
and activate specific clone without prior processing
28 Allergology International Vol 55, No1, 2006 http:www.jsaweb.jp
Roujeau J
by the antigen presenting cell and through a non co-
valent binding to the MHC or its embedded pep-
tide.12,14,17 Actually some specific TCR could recog-
nize sulfamethoxazole presented either in covalent or
noncovalent bound form, but the former was the ex-
ception and the later the rule.18
Since the non covalent binding is reminiscent of
the pharmacological interaction between a drug and
its receptor, the denomination of pharmoco-immune
(p-i)concept has been proposed.17
Often the recognition by the TCR was not abso-
lutely specific. For example, lidocaine specific clones
also reacted to mepivacaine and vice versa19 and SMX
specific clones reacted to a few other antibacterial sul-
fonamides but neither to Cox-2 antagonist NSAIDS
nor to furosemide .18 Anyhow since the in vivo re-
sponse to medications is not clonal , these in vitro
data on cross-reactivity should not be extrapolated
too quickly to clinical practice．
WHAT IS THE ANTIGEN: PARENT DRUG OR
A REACTIVE METABOLITE？
Twenty years ago it has been proposed that reactive
metabolites played a key role in hypersensitivity reac-
tions to drugs, by allowing the covalent binding of
metabolites to proteins , when the parent forms of
most drugs are not reactive. According to the hapten
theory such a binding to proteins was required for in-
itiating an immune response to small non protein
molecules like medications. In the serum of patients
with hepatitis due to tienilic acid antibodies were
found that reacted against a covalent complex of the
reactive metabolite with the CYP450 enzyme that pro-
duced it.20 The hypothesis of drug reactive metabo-
lites was essentially developed about sulfonamides. It
was initially based on a report that among 5 patients
with hypersensitivity to sulfamethoxazole ( SMX ) 4
were slow acetylators and 1 had an “ intermediate
phenotype”.21 From this observation the theory was
proposed that impaired acetylation of SMX led to in-
creased metabolism through oxidation pathways ,
with elevated production of reactive metabolites
(SMX-NHOH and SMX-NO) that behaved as hap-
tens.21 That was rapidly accepted as a dogma after be-
ing comforted by a few additional data. Some series
found that slow acetylation phenotype or genotype
was a risk factor for allergy to sulfonamides,22,23 espe-
cially in patients with AIDS.24 On the other hand two
large prospective cohorts in HIV positive patients
treated with sulfonamides did not find any significant
impact of slow acetylation genotype or phenotype on
the risk of cutaneous reaction.25,26
More recently it was demonstrated that SMX-NO
was immunogenic in rats , mice and rabbits while
SMX was not . 27 But lymphocytes from immunized
animals reacted only to metabolites and not to the
parent drug . There is therefore no indication that
priming of T-cells with reactive metabolites of SMX
may result in reactivity towards the parent drug．
In humans the list is already long of T-lymphocyte
clones that react to the parent form of drugs and only
occasionally to reactive metabolites. That was shown
for SMX 18 phenobarbital 14 and lamotrigine . 15 Re-
duced glutathione by modifying the relative concen-
tration of SMX and SMX-NO abrogated the response
of SMX-NO specific T-cell clones and enhanced the
proliferation of SMX specific clone . That indicated
that T cells from allergic humans recognize the non
covalently bound parent drug rather than SMX-NO
fixed on the membrane of antigen presenting cells.28
One important point in this discussion is to esti-
mate the concentration of reactive metabolites that
can be expected in vivo in human in the intercellular
milieu of epidermal cells , or on the membrane of
keratinocytes that are the targets of cytotoxic T cells
in drug eruptions. There are no vessels in the epider-
mis. Cells and nutrients have to cross the basement
membranes of dermal capillaries and of the dermo-
epidermal junction. Precisely because of their very
high chemical reactivity it is unlikely that free and
still reactive nitroso-SMX can reach the epidermis
from the blood . Several teams have demonstrated
that keratinocytes can metabolize drugs and produce
reactive metabolites locally. But unlike hepatocytes,
epidermal cells are not “professional” metabolizers
and the amounts of reactive metabolites that they are
capable to produce are very low. For example normal
human keratinocytes in culture incubated with 1
mMole SMX(the upper range of concentration in the
blood of patients taking high daily doses), produced 1
nMole i.e. about 250 picogrammeml SMX-NHOH,
precursor of SMX-NO . 29 It has not been demon-
strated that such in situ production of reactive me-
tabolites was capable to initiate an immune reaction.
In vitro elicitation of a T-cell response to SMX-NHOH
and to SMX-NO was observed at concentrations of 25
μgml and 1 μgml respectively,27 i.e. 105 times more
than what was produced by keratinocytes in culture.
WHY IS THE IMMUNE RESPONSE TO MEDI-
CATIONS LEADING TO SO DIVERSE REAC-
TIONS？
We will not discuss here the mechanisms of immedi-
ate hypersensitivity, IgE specific or not, but will focus
only on delayed reactions, mediated by T-cells. Spe-
cific T cells were actually detected in a variety of drug
eruptions．
Some answers were provided by studying effectors
cells obtained at the site of abnormal reactions. Drug-
specific cytotoxic T-cells were found in the bronchoal-
veolar fluid of patients with minocycline hypersensi-
tivity pneumonitis30 as well as in the skin lesions of
fixed drug eruptions31 and of toxic epidermal necroly-
sis.32
Fixed drug eruption is a fascinating model. Local-
ized blisters recur at the same site a few hours after
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drug reintroduction. This is usually not harmful, al-
lowing provocation tests, with sequential biopsies al-
lowing to decipher the mechanisms. In this disease
there are CD8+ effector memory cells remaining at
the site of the lesions within the epidermis or at the
junction between epidermis and dermis. Even when
resting these cells express early activation markers
(CD69)and a few hours after drug re-administration
produce high amounts of IFN gamma, before the on-
set of apoptosis of epidermal cells.31
In TEN, blisters that result from accumulation of
interstitial fluid under the apoptotic epidermis33 con-
tain T-lymphocytes with a phenotype of cytotoxic
cells. In 46 patient suffering from TEN, these cells
killed autologous lymphocytes and keratinocytes in a
drug specific , class I restricted and perforingran-
zyme mediated pathway . 34 The only cytokine that
was produced by these effector cells was
IFN-gamma.35
On the other hand, drug specific CXCL8 producing
clones were obtained from skin tests of patients with
acute generalized exanthematous pustulosis, a neu-
trophil mediated drug reaction.6
One may therefore assume that the final phenotype
of drug eruptions results from the nature of effectors:
cytotoxic T-cells in blistering reactions, T-cells releas-
ing specific chemokines for reactions mediated by
neutrophils or eosinophils．
But that is probably too simple since drug specific,
MHC restricted and perforingranzyme mediated cy-
totoxicity was also observed in T-Cell clones(remark-
ably CD4 + or CD8 + ) isolated from patients with
maculo-papular benign eruptions.13,16
It is not yet clear whether the huge differences be-
tween clinical patterns of drug allergies that are re-
lated to delayed hypersensitivity result from an im-
mune response of different intensity, different quality
or both.
Comparing fixed drug eruption and TEN leads to
some other key questions. Both are drug induced
blistering diseases, characterized by apoptosis of epi-
dermal cells, and seem related to the same cytotoxic
effectors. The former is localized, with few constitu-
tional symptoms. The later is disseminated with high
morbidity. The finding of IL10 producing CD4 T-cells
in the lesions of fixed drug eruption suggests the role
of regulatory T-cells in limiting the extension of the
reaction.36
Recently a transgenic mouse model of TEN sug-
gested that specific anti-OVA cytotoxic T-cells killed
OVA expressing keratinocytes only in a context of im-
mune suppression.37 The absence of lesions in ani-
mals with a normal immune system depended on
both CD4+CD25+ regulatory T-cells and on CD11c+
dendritic cells.38
This concept of negative regulation should be inte-
grated in the theoretical models of drug allergy.
RISK FACTORS OF DRUG ALLERGY
Medications have been elaborated for treating dis-
eases. It is therefore not surprising that among pa-
tients with adverse reaction to anticonvulsants there
are more epileptics than in a control population. But
epilepsy does not appear to increase the risk in com-
parison with patients using the same drugs for neu-
ralgia or for psychiatric disorders . In other words
there is no positive interaction between epilepsy and
allergy to anticonvulsants. Epilepsy is not a risk factor
by any other way than leading to anticonvulsants in-
take.
On the other hand there are evidences that some
diseases increase the risk of drug allergy.
Several authors pointed to a striking frequency of
severe drug eruptions in patients with brain tumors
treated with an association of X-Ray therapy, anticon-
vulsants and corticosteroids．
Systemic lupus erythematosus and more generally
collagen vascular diseases were shown to increase
the risks of benign drug eruptions and also of SJS
TEN.39
More attention was devoted to viral infections as
possible risk factors of allergy to medications. The
most striking , but poorly evaluated , model is the
nearly constant eruption that occurs when adolescent
are given aminopenicillins during infectious mononu-
cleosis. Since the eruption usually does not recur if
the same drug is taken again after remission of acute
EBV infection , it is often considered to be a non-
allergic phenomenon. Anyhow specific immune reac-
tion to amoxicillin was recently evidenced in 3 of 4 pa-
tients investigated.40 If confirmed in larger numbers,
this finding would suggest that the amoxicillin rash
occurring in infectious mononucleosis is drug spe-
cific and that its expression is enhanced by viral infec-
tion. It has been also established that HIV infection
increases the risk of drug allergy. That was true for
many drugs but mainly evaluated with SMX, a drug
already known for a rather high rate of reactions in
non HIV infected population and which was largely
used by AIDS patients in the first decade of the pan-
demic. Up to 40% of patients had skin reactions when
treated with high doses and about 15% reacted to
usual dosage that induced 3 to 5% eruptions in non
HIV populations . How AIDS promoted allergy to
medication has not received yet a plausible explana-
tion. Most hypotheses focused on abnormal metabo-
lism , but two large prospective studies found no
metabolic explanation to this increased risk. The prin-
cipal factor of risk was a higher number of CD8+ T-
cells. Activation of other viruses(CMV, EBV, HHV6)
appeared to play no role.41
It has been also demonstrated that a special type of
drug reactions, the so-called “Drug Hypersensitivity
Syndrome” or “Drug Reaction with Eosinophilia and
Systemic Symptoms” was often associated with reac-
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tivation of herpes viruses(HHV6, CMV, EBV).42,43
This multi organ reaction to a variety of drugs(anti-
convulsants , allopurinol , dapsone , minocycline ) is
characterized by a later onset than for other allergic
reactions(usually 2―4 weeks instead of 1―2 weeks)
and an expansion of activated lymphocytes. Virus re-
activation may explain some clinical symptoms(rash,
hepatitis, encephalitis)as well as lymphocytosis . In
some instances virus DNA was not detected in the
blood at the onset of the reaction but only several
days later. The mechanisms of interactions between
drugs and viruses are therefore probably different
here from what happens during EBV primary infec-
tion and AIDS．
Several hypotheses were proposed to explain the
interactions between viral infections and drug allergy.
The first is that viruses impair drug metabolism
either directly or through the inflammatory response
to infection.
Some medications may induce hypogammaglobu-
linaemia and promote virus reactivation, the symp-
toms being those of viral disease and not of drug al-
lergy.43 That has been proposed for DHSDRESS but
does not explain cases with evidence of drug specific
immune reactivity(positive skin tests, positive rechal-
lenge)．
Viral infection could trigger recognition of drugs as
antigens, as well as other “danger signals” that are
suspected to enhance the immune response．
Another hypothesis is that recognition of drugs as
antigen may be rather common, while the expression
of the immune response is repressed under normal
circumstances. Viral infection may impair the nega-
tive regulation and promote a reaction.
Recent literature showed that genetic factors may
be strong predictors of severe drug reactions. Hyper-
sensitivity to abacavir was strongly associated with
HLA B*5701.44,45 In Taiwan, within an homogeneous
Han Chinese population a 100% association was ob-
served between SJS or TEN related to carbamazepine
and HLA B*150246 and another 100% association be-
tween SJS, TEN or DRESS related to allopurinol and
HLA B*5801 47 These observations have important
theoretical implications. By pointing to HLA genes
they strongly support a key role for immune mecha-
nisms. But since the associations found in Taiwan are
far from being so strong in other countries , 48 the
practical applications are probably not at hand．
FROM IMPROVED KNOWLEDGE OF
MECHANISMS TO PREVENTION AND
TREATMENT OF DRUG ALLERGY
We are not yet very close of clinical application of the
above progresses. Even though most drug reactions
are related to immune response in vitro and in vivo
tests have too low sensitivity and predictive values to
be really helpful, and the role of a specific drug re-
mains difficult to demonstrate in individual patients.
There is also no consensus on what of the new find-
ings on genetics could be applied now. In some re-
stricted groups of patients, for treatments that can be
delayed, such as antiretroviral therapy in AIDS some
physicians already recommend HLA typing before in-
itiating abacavir. But there is no consensus on such
attitude, because the predictive values of the test are
not yet definitely settled.
Because of growing suspicion that genetics matters
it seems already prudent to recommend avoidance of
the suspected drug to all blood relatives of a patient
with a severe adverse reaction.
The more we learn on cross reactivity, the more it
seems restricted to medications with close structural
resemblance . It is probably useless to provide pa-
tients with to broad lists of medications that should
be contra-indicated．
We should also reconsider the use of treatments
like corticosteroids, cyclosporine or other immuno-
modulating agents for blocking the cytotoxic reaction
in severe life-threatening drug allergy．
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